National Institute of Allergy and Infectious Diseases

PDS Biotech Announces Preclinical Publication in Peer Reviewed Viruses Journal Showing Superior CD4 T Cell Induction by Infectimune™

Retrieved on: 
星期四, 二月 16, 2023
Vaccine, Viral, SARS-CoV-2, PDS, Vaccination, CD4, CpG, Biotechnology, University, Research, Immunology, PDSB, Civics, Infection, National Institute of Allergy and Infectious Diseases, Interferon, CD8, Cancer, Doctor of Philosophy, Virus

The preclinical research studied Infectimune™, PDS Biotech’s novel investigational infectious disease immune activating platform, and demonstrated the technology’s potency in eliciting CD4 T cells.

Key Points: 
  • The preclinical research studied Infectimune™, PDS Biotech’s novel investigational infectious disease immune activating platform, and demonstrated the technology’s potency in eliciting CD4 T cells.
  • The studies focused on comparing Infectimune™ induced immune responses following primary vaccination against influenza with immune responses induced by leading vaccine adjuvants.
  • This publication follows a recent article in Viruses highlighting the ability of Infectimune™ to generate a broad immune response against viruses, including SARS-CoV-2 and multiple strains of influenza.
  • Results from the study concluded that Infectimune™ dramatically enhanced CD4 T cell responses to recombinant HA-B proteins relative to AddaVax™ and AddaVax™ plus CpG.

Humanetics Corporation Announces Positive Results from Independent Data Monitoring Committee Review of Phase 2 Clinical Trial

Retrieved on: 
星期三, 二月 15, 2023
Pharmaceutical, Homeland Security, Defense, Oncology, Other Science, Research, Military, Law Enforcement, Emergency Services, Other Defense, Contracts, Public Policy, Government, Clinical Trials, Biotechnology, Health, Women, Seniors, Men, General Health, Family, Science, COVID-19, Consumer, Other Health, DSMB, Human services, Patient safety, BIO, United States Department of Health and Human Services, Bangladesh Technical Education Board, Safety, Patient, Clinical trial, Infection, Radiation, Contract manufacturing organization, Lung cancer, United States Department of Defense, National Institute of Allergy and Infectious Diseases, Data monitoring committee, Pharmaceutical industry, Humanetics

Humanetics Corporation (Humanetics) is pleased to announce the positive results from the independent Data Safety Monitoring Board (DSMB) review of its phase 2 clinical trial of BIO 300 in patients with COVID-19.

Key Points: 
  • Humanetics Corporation (Humanetics) is pleased to announce the positive results from the independent Data Safety Monitoring Board (DSMB) review of its phase 2 clinical trial of BIO 300 in patients with COVID-19.
  • The phase 2 clinical trial is evaluating the safety and efficacy of BIO 300, a novel treatment designed to prevent long-term lung complications in COVID-19 patients.
  • "We are extremely pleased with the positive results from the DSMB review, as they provide support to continue with this important clinical trial," said Ronald J. Zenk, CEO of Humanetics.
  • Humanetics recently completed a phase 1b/2a clinical trial in lung cancer patients ( NCT02567799 ).

Newly Developed RSV Vaccine Offers Immunity While Lowering the Risk of Dangerous Pulmonary Inflammation

Retrieved on: 
星期一, 一月 30, 2023
ACT, Safety, TLR2, University, Malaria, Veterinary medicine, Immunology, Inflammation, Bangladesh Technical Education Board, University of Georgia College of Veterinary Medicine, Viral, Immunity, Infection, National Institute of Allergy and Infectious Diseases, Volunteering, RSV, Vaccine, Protein, Mouse, T helper cell, Bronchiolitis, Volume Ten, Pneumonia, Clinical trial, Eosinophil, Antibody, LBL, Research, CHMI, Pharmaceutical industry, HAVEN

NEW HAVEN, Conn., Jan. 30, 2023 /PRNewswire/ -- Scientists at Artificial Cell Technologies (ACT) have developed a fully synthetic microparticle vaccine for Respiratory Syncytial Virus (RSV)  that elicited a protective immune response in mice while simultaneously lowering pulmonary inflammation after exposure to the virus. New results of their preclinical research have been published in the journal Vaccines.

Key Points: 
  • A major risk of RSV infection is the potential for severe pulmonary inflammation characterized by bronchiolitis and pneumonia.
  • In the 1960s, clinical trials of a formalin-inactivated (FI-RSV) vaccine were halted when more vaccinated children were hospitalized after RSV infection compared to those who were not vaccinated.
  • "An effective RSV vaccine must protect against infection without priming the host for excessive inflammation," says Jeff Powell, Ph.D., Vice President of Immunology at ACT.
  • ACT is currently preparing for a Phase 1b controlled human malaria infection (CHMI) clinical trial of its malaria vaccine.

Mount Sinai Researchers Awarded $12 Million NIH Grant to Create a Center to Unravel Novel Causes of Food Allergy & Atopic Dermatitis That Uses a Systems Biology Approach

Retrieved on: 
星期四, 一月 26, 2023
University of North Carolina at Pembroke, University, Sunbeam, Atopic dermatitis, MPH, Johns Hopkins, Diagnosis, Bangladesh Technical Education Board, Skin, Infection, National Institute of Allergy and Infectious Diseases, Systems biology, Anaphylaxis, Periodic breathing, Master of Philosophy, Sinai, Risk, Dermatitis, Food allergy, Chapel Hill, Principal, Parent, National Jewish Health, Biology, Food, Allergy, Vaccine, MD, Northwestern

NEW YORK, Jan. 26, 2023 /PRNewswire-PRWeb/ -- Mount Sinai researchers have been awarded $12 million over five years by the National Institutes of Health to create a center to elucidate novel causes of, and contributing factors to, food allergies and atopic dermatitis.

Key Points: 
  • Mount Sinai researchers have been awarded $12 million over five years by the National Institutes of Health to create a center to elucidate novel causes of, and contributing factors to, food allergies and atopic dermatitis.
  • The Systems Biology of Early Atopy (SunBEAm) Analysis and Bioinformatics Center intends to develop a better understanding of allergy development.
  • NEW YORK, Jan. 26, 2023 /PRNewswire-PRWeb/ -- Mount Sinai researchers have been awarded $12 million over five years by the National Institutes of Health to create a center to elucidate novel causes of, and contributing factors to, food allergies and atopic dermatitis.
  • The Systems Biology of Early Atopy (SunBEAm) Analysis and Bioinformatics Center intends to develop a better understanding of allergy development.

PDS Biotech Announces Publication of Preclinical Infectimune™ Based Vaccine Studies Demonstrating Effective Protection Against Viral Infection in Peer-Reviewed Journal, Viruses

Retrieved on: 
星期三, 二月 8, 2023
Biotechnology, Cancer, Infection, Vaccine, Animal, COBRA, CD4, Immune system, University, National Institute of Allergy and Infectious Diseases, Influenza and Other Respiratory Viruses, Severe acute respiratory syndrome coronavirus 2, CD8, PDS, Research, PDSB, Mouse, Virus

The paper, titled, “Recombinant Protein Vaccines Formulated with Enantio-Specific Cationic Lipid R-DOTAP Induce Protective Cellular and Antibody-Mediated Immune Responses in Mice,” highlighted results from preclinical studies.

Key Points: 
  • The paper, titled, “Recombinant Protein Vaccines Formulated with Enantio-Specific Cationic Lipid R-DOTAP Induce Protective Cellular and Antibody-Mediated Immune Responses in Mice,” highlighted results from preclinical studies.
  • It was found that Infectimune™ (R-DOTAP) promoted strong T cell and antibody immune responses in both single- and multi-viral antigen (protein) containing vaccines.
  • The vaccines induced antigen-specific and multi-cytokine-inducing CD8 and CD4 T cells associated with antigen-specific killing and immune memory, respectively.
  • Importantly, these Infectimune™ induced neutralizing antibody and T cell responses completely protected animals from lethal challenges with live SARS-CoV-2 and influenza viruses.

Aligos Therapeutics Announces Strategic Reprioritization of NASH and COVID-19 Programs and Confirms Key Timelines and Extension of Cash Runway to Year-End 2024

Retrieved on: 
星期三, 二月 8, 2023
MSD, Pathogen, MBA, CHB, National Institute of Allergy and Infectious Diseases, Infection, COVID-19, Plasma protein binding, Metropolitan, Rega Institute for Medical Research, GLP, Sirna, Therapy, NASH, Jacob Aligo, NIH, Leuven Centre for Global Governance Studies, NIAID, Patient, Fatty liver disease, SAN, Merck, Merck & Co., Degenerative disease, SAD, Liver disease, Workforce, Drug design, Doctor of Philosophy, Discovery, Research, KU Leuven, Pharmaceutical industry

SOUTH SAN FRANCISCO, Calif., Feb. 08, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in NASH and viral diseases, today announced a portfolio reprioritization. Aligos’ highest priorities will be focused on rapid advancement of its clinical NASH (ALG-055009) and COVID-19 (ALG-097558) programs as well as maintaining its ongoing NASH oligonucleotide research collaborations with Merck & Co. (MSD outside the U.S. and Canada). Additionally, the Company plans to complete the ≤48-week (ALG-000184) and single ascending dose (ALG-125755) cohorts for its two chronic hepatitis B programs and continue to invest in selected research programs and collaborations with external research organizations.

Key Points: 
  • As a result of the portfolio reprioritization, realignment of its workforce, and other cost-saving measures, the Company expects to maintain a strong balance sheet and extend its projected cash runway to the end of 2024.
  • “I would like to express my sincere gratitude to the employees who are being affected by this reprioritization.
  • ALG-055009 – the Company’s THR-β agonist in development for NASH is expected to complete an ongoing Phase 1 study in H1 2023.
  • Aligos plans to continue to support its collaboration agreements, including the agreement with Merck & Co. to develop oligonucleotide candidates to address NASH.

Blue Water Vaccines Announces Partnership with AbVacc for Joint Development of Novel Monkeypox and Marburg Vaccine Candidates

Retrieved on: 
星期三, 二月 1, 2023
Vaccine, Family, Human, Smallpox, Integration, Blood, Epidemic, Animal, Korea Disease Control and Prevention Agency, BWV, Patient, National Institute of Allergy and Infectious Diseases, Monkeypox, Partnership, WHO, MVD, Marburg virus disease, World Health Organization, Infection, Research, Water, IBT, Pharmaceutical industry

CINCINNATI, Ohio, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or the “Company”), a biopharmaceutical company developing transformational vaccines to address significant global health challenges, today announced a collaboration with AbVacc, Inc. (“AbVacc”) for the joint development of vaccine candidates targeting monkeypox and Marburg virus disease (“MVD”).

Key Points: 
  • CINCINNATI, Ohio, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or the “Company”), a biopharmaceutical company developing transformational vaccines to address significant global health challenges, today announced a collaboration with AbVacc, Inc. (“AbVacc”) for the joint development of vaccine candidates targeting monkeypox and Marburg virus disease (“MVD”).
  • BWV previously announced plans to explore a novel monkeypox vaccine candidate using this platform and under this agreement, AbVacc & BWV plan to work collaboratively to optimize the vaccine design and conduct preclinical immunogenicity and efficacy studies.
  • In addition to monkeypox vaccine development, AbVacc will utilize its extensive expertise in MVD to develop a novel vaccine targeting Marburg virus using BWV’s VLP platform.
  • There are two vaccines approved for prevention of monkeypox disease in the United States, but limited availability of either vaccine resulted in increased spread of monkeypox within the U.S. and internationally.

Adaptive Phage Therapeutics Announces First Patient Dosed in the PHAGE Clinical Trial Evaluating Phage Therapy in Cystic Fibrosis-related Respiratory Infection

Retrieved on: 
星期四, 一月 12, 2023
Biotechnology, Other Health, Health, Pharmaceutical, Clinical Trials, Infection, NIAID, Therapy, Cystic fibrosis, Virus, Quality of life, Safety, Pseudomonas aeruginosa, Bacteria, Walter Reed Army Institute of Research, WRAIR, National Institute of Allergy and Infectious Diseases, Health, Patient, APT, CF, Clinical trial, Multimedia, Volunteering, Mucus, NIH, Bacteriophage, Pharmaceutical industry, Vaccine

The trial is evaluating whether the bacteriophage, or “phage,” therapy is safe and able to reduce the amount of bacteria in the lungs of volunteers.

Key Points: 
  • The trial is evaluating whether the bacteriophage, or “phage,” therapy is safe and able to reduce the amount of bacteria in the lungs of volunteers.
  • ARLG is funded by the National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health (NIH).
  • View the full release here: https://www.businesswire.com/news/home/20230112005238/en/
    "At Adaptive Phage Therapeutics, we are committed to developing innovative treatments that address the growing problem of antibiotic resistance," said Greg Merril, CEO of Adaptive Phage Therapeutics.
  • The PHAGE trial is enrolling CF patients who chronically harbor P. aeruginosa in their respiratory tracts.

University of South Florida Health, Northwell Health, Tampa General Hospital and Formlabs earn national recognition for 3D-printed nasal swab used in pandemic

Retrieved on: 
星期四, 一月 12, 2023
Patents for Humanity, PARK, Hospital, COVID-19 testing, University, Medical/Market Center station, Temperature, Internal medicine, Regeneron Pharmaceuticals, Patent, COVID-19, University of Texas Health Science Center Department of Radiology, Pressure, Tampa General Hospital, Health, Gilead Sciences, 3D, Humanity, National Institute of Allergy and Infectious Diseases, Formlabs, Patient, University of South Florida, Thomas Jefferson University Hospital, Clinical trial, NP, USF Health Byrd Alzheimer's Institute, Infection, Northwell Health, Innovation, USF, Doctor of Philosophy, NIH, 3D printing, Pharmaceutical industry, Medicine, Management, MD, Radiology

TAMPA, Fla. SOMERVILLE, Mass. and NEW HYDE PARK, N.Y., Jan. 12, 2023 /PRNewswire/ -- The University of South Florida (USF) has been awarded the Patents for Humanity award by the U.S. Patent and Trademark Office (USPTO) for its patent of the 3D-printed nasopharyngeal (NP) swab, created in the early part of the pandemic as a solution to the disrupted commercial production of standard flocked NP swabs critical in diagnostic testing for COVID-19.

Key Points: 
  • All will be honored by the USPTO at an awards ceremony on February 16, 2023.
  • USF is earning this recognition for its innovative solution to the commercial NP swab shortage.
  • From that point on , the USF/Northwell design was shared with hospitals, health systems, the military, and clinics around the globe.
  • Formlabs is proud to be recognized alongside USF Health, Northwell Health, and Tampa General Hospital in the USPTO Patents for Humanity COVID-19 category."

TeraImmune Extends CRADA for Development of Treg Expansion for Clinical Use

Retrieved on: 
星期三, 一月 4, 2023
National Institute of Allergy and Infectious Diseases, Clinical trial, Multiple sclerosis, Research, CRADA, Infection, Development, NIAID, Degenerative disease, NIH, Atopic dermatitis, Doctor of Philosophy, Helios, Cooperative research and development agreement, Vaccine, Regulatory T cell

The CRADA is entitled “Developing the process of human regulatory T cells for clinical use.”

Key Points: 
  • The CRADA is entitled “Developing the process of human regulatory T cells for clinical use.”
    Under the agreement, TeraImmune continues to develop cGMP-compliant manufacturing protocol for its lead candidate, TI-168, and clinical laboratory manuals designed to provide relevant tactical support for the upcoming clinical trial.
  • NIAID provides scientific advice on the therapeutic use of Tregs and on establishing cGMP-grade Treg manufacturing processes, as well as assists in the development of standard operating procedures for the preclinical and clinical stage development of cGMP-grade Treg cell therapy.
  • TeraImmune licensed one of its key technologies for a stable expansion of functional regulatory T cells from NIAID.
  • “We are excited to continue our cooperative research with Dr. Shevach,” said Yong Chan Kim, PhD, Chief Executive Officer of TeraImmune.